The Johnson & Johnson Pharmaceutical Companies

Individually and collectively, the Johnson & Johnson pharmaceutical operating companies actively seek new alliances, such as licensing, co-development and co-marketing agreements in their therapeutic areas of interest, as well as in new business areas. Each company has a proven track record of creating and maintaining mutually beneficial partnerships.

ALZA Corporation www.alza.com

Since 1968, ALZA Corporation has been a pioneer and leader in the research and development of drug delivery technology. Today, ALZA is leading the next generation of drug delivery, drawing on the wide-ranging and multi-disciplinary scientific experience of our professionals and the strength of our partnering relationships to develop differentiated and superior medicines.

The commitment to develop solutions that address unmet patient needs has resulted in the industry's most extensive portfolio of drug delivery-based pharmaceuticals that is unparalleled in breadth and commercial success. It includes oral, transdermal, implantable and liposomal technologies. ALZA's current pipeline includes more than 30 projects in development for Johnson & Johnson, and a number of external partner development programs and research collaborations.

ALZA's technology solutions focus on solving the most complex challenges in drug delivery and targeting. Its delivery technologies can address many drug development hurdles, including poor solubility, low bioavailability, undesirable PK/PD and the delivery of biopharmaceuticals and proteins. Ongoing research is focused on finding new solutions and technologies to address the medical and drug delivery needs of the future.

Partnering is a key part of our strategy. Through in-licensing relationships, research collaborations, and strategic alliances, ALZA can provide value to partners in all phases of product development. Uniquely positioned as part of Johnson & Johnson, ALZA is actively exploring product opportunities that combine delivery technology with new chemical entities, biopharmaceuticals and drug/device concepts.